CR20210466A - Biomarcadores salivales de lesión cerebral - Google Patents

Biomarcadores salivales de lesión cerebral

Info

Publication number
CR20210466A
CR20210466A CR20210466A CR20210466A CR20210466A CR 20210466 A CR20210466 A CR 20210466A CR 20210466 A CR20210466 A CR 20210466A CR 20210466 A CR20210466 A CR 20210466A CR 20210466 A CR20210466 A CR 20210466A
Authority
CR
Costa Rica
Prior art keywords
brain injury
salivary biomarkers
tbi
diagnosing
predicting
Prior art date
Application number
CR20210466A
Other languages
English (en)
Inventor
Antonio Belli
Pietro Valentina Di
Original Assignee
Marker Diagnostics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marker Diagnostics Uk Ltd filed Critical Marker Diagnostics Uk Ltd
Publication of CR20210466A publication Critical patent/CR20210466A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los métodos de diagnóstico, monitoreo, tratamiento y predicción del curso de la lesión cerebral traumática (LCT), que incluye la lesión cerebral traumática leve (LCTL), incluyen determinar un nivel de al menos un biomarcador de ARN (por ejemplo, miARN) en una muestra de saliva de un sujeto. También se describen elementos sensores, sistemas de detección, composiciones y estuches para diagnosticar, monitorear, tratar y predecir el curso de la LCT
CR20210466A 2019-02-14 2020-02-14 Biomarcadores salivales de lesión cerebral CR20210466A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805761P 2019-02-14 2019-02-14
US201962884104P 2019-08-07 2019-08-07
PCT/IB2020/051273 WO2020165863A2 (en) 2019-02-14 2020-02-14 Salivary biomarkers of brain injury

Publications (1)

Publication Number Publication Date
CR20210466A true CR20210466A (es) 2022-02-08

Family

ID=69740439

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210466A CR20210466A (es) 2019-02-14 2020-02-14 Biomarcadores salivales de lesión cerebral

Country Status (17)

Country Link
US (1) US20220380850A1 (es)
EP (1) EP3924518A2 (es)
JP (1) JP2022520427A (es)
KR (1) KR20220002867A (es)
AU (1) AU2020220963A1 (es)
BR (1) BR112021015845A2 (es)
CA (1) CA3129034A1 (es)
CL (1) CL2021002121A1 (es)
CO (1) CO2021011964A2 (es)
CR (1) CR20210466A (es)
IL (1) IL285446A (es)
MX (1) MX2021009829A (es)
PE (1) PE20220877A1 (es)
SG (1) SG11202108664RA (es)
TW (1) TW202045734A (es)
WO (1) WO2020165863A2 (es)
ZA (1) ZA202106673B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4314341A1 (en) * 2021-04-02 2024-02-07 Marker Holdings AG Biomarkers of musculoskeletal injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130022982A1 (en) * 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
WO2015134551A1 (en) * 2014-03-03 2015-09-11 Banyan Biomarkers, Inc. Micro rna markers for diagnosis of a neurological condition
GB201603967D0 (en) 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
AU2018240473B2 (en) * 2017-03-23 2023-12-14 Penn State Research Foundation Analysis and prediction of traumatic brain injury and concusion symptoms

Also Published As

Publication number Publication date
KR20220002867A (ko) 2022-01-07
EP3924518A2 (en) 2021-12-22
ZA202106673B (en) 2024-02-28
PE20220877A1 (es) 2022-05-27
BR112021015845A2 (pt) 2021-10-05
WO2020165863A3 (en) 2020-09-24
CO2021011964A2 (es) 2021-12-10
TW202045734A (zh) 2020-12-16
WO2020165863A2 (en) 2020-08-20
JP2022520427A (ja) 2022-03-30
MX2021009829A (es) 2021-12-10
US20220380850A1 (en) 2022-12-01
CL2021002121A1 (es) 2022-03-25
CA3129034A1 (en) 2020-08-20
IL285446A (en) 2021-09-30
SG11202108664RA (en) 2021-09-29
AU2020220963A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
EP4257705A3 (en) Biomarkers of traumatic brain injury
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
WO2014201516A3 (en) Biomarker identification
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
GB2484764B (en) Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies
ZA200701188B (en) Use of C3a and derivatives thereof as a biomarker for colorectal ademona and/or carcinoma; diagnosis method and test system using the same
WO2015164431A3 (en) Methods, processes, devices and kits for the measurement of post traumatic stress disorder microrna markers
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
BR112018073214A2 (pt) métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
ZA202106673B (en) Salivary biomarkers of brain injury
NZ729773A (en) Biomarkers for disease progression in melanoma
GB2494580A (en) Method for diagnosing lung cancer
EP2415877A3 (en) Means and methods for diagnosing pancreatic cancer
WO2019204340A3 (en) Biomarker for predicting equine gait and methods of use thereof
MX2019008005A (es) Metodos y composiciones para diagnosticar preeclampsia.
ATE541413T1 (de) Verfahren und system zur detektion akustischer erschütterungen und anwendung des verfahrens in hörgeräten
WO2020115270A3 (en) Biomarker for detecting zearalenone effect
EA202192186A1 (ru) Слюнные биомаркеры травмы головного мозга
TR201814812A2 (tr) Performans ölçme prosesi̇
WO2019053117A8 (en) Pct and pro-adm as markers for monitoring antibiotic treatment
WO2018208749A8 (en) PROSTATE CANCER GENE PROFILES AND THEIR METHODS OF USE
NO20080510L (no) Anvendelse av endoplasminfragment og derivater derav som biomarkor for colorektal adenom og/eller karsinom, samt testsystem og fremgangsmate for deteksjon
WO2021138273A3 (en) Autoantibodies as biomarkers for autoimmune polyglandular syndrome type 1
AR118109A1 (es) Composición, equipo médico, elemento sensor, sistema y método de detección de biomarcadores para su uso en lesiones cerebrales traumáticas
WO2020127499A3 (en) Mirnas as biomarkers for parkinson's syndrome